Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antidepressant Long-Term Efficacy Pre-Approval Will Be Voted On By Cmte.

Executive Summary

FDA will ask whether it is reasonable to require both acute and long-term efficacy data in applications for antidepressants and other chronic psychiatric drugs at its Psychopharmacologic Drugs Advisory Committee meeting on Oct. 25

You may also be interested in...

Psychopharm Cmte. Crafts Statement To Avoid Public Misunderstanding

FDA's Psychopharmacologic Drugs Advisory Committee crafted a statement on the need for long-term efficacy data for psychiatric drugs in order to avoid public misperception of the outcome of its Oct. 25 meeting

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts